Haemonetics Cash Flow Statement
HAE / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | $167.7M | $117.6M | $115.4M | $43.4M | $79.5M | $76.5M | $55.0M | $45.6M | -$26.3M | -$55.6M | $16.9M | $35.1M | $38.8M | $66.9M |
| Depreciation & Amortization | - | $115.6M | $97.2M | $93.3M | $97.7M | $84.3M | $110.3M | $109.4M | $89.2M | $89.7M | $89.9M | $86.1M | $81.7M | $65.5M | $50.0M |
| Operating Cash Flow | - | $181.7M | $181.8M | $273.1M | $172.3M | $108.8M | $158.2M | $159.3M | $220.3M | $159.7M | $121.9M | $127.2M | $139.5M | $85.1M | $115.3M |
| Capital Expenditures | - | $39.3M | $38.1M | $191.3M | $96.5M | $37.0M | $48.8M | $119.0M | $74.8M | $76.1M | $102.4M | $122.2M | $73.6M | $62.2M | $53.2M |
| Free Cash Flow | - | $142.4M | $143.6M | $81.7M | $75.8M | $71.8M | $109.5M | $40.3M | $145.6M | $83.6M | $19.5M | $5.0M | $65.9M | $22.9M | $62.1M |
| Share Buybacks | - | $225.0M | $0 | $75.0M | $0 | $0 | $175.0M | $160.0M | $100.0M | $0 | $61.0M | $39.0M | $0 | $50.0M | $50.0M |
| FCF Margin | - | 10.5% | 11.0% | 7.0% | 7.6% | - | - | - | 64.6% | 9.4% | 2.1% | 0.5% | 7.0% | 2.6% | 8.5% |